Results 101 to 110 of about 74,631 (338)

Mild behavioral impairment in Parkinson's disease: Data from the Parkinson's disease cognitive impairment study (PACOS) [PDF]

, 2019
Neuropsychiatric symptoms (NPS) have been frequently described in Parkinson's disease (PD), even in the earliest stages of the disease. Recently the construct of mild behavioral impairment (MBI) has been proposed as an at-risk state for incident ...
Baschi R., Cicero C. E., Luca A., Monastero R., Nicoletti A., Recca D., Restivo V., Zappia M.   +7 more
core   +1 more source

Acute Levodopa Challenge in Atypical Parkinsonism: Comprehensive Analysis of Individual Motor Responses

Brain Sciences
The acute levodopa challenge is widely used to distinguish Parkinson’s disease (PD) from atypical parkinsonian syndromes (APSs) such as multiple system atrophy (MSA) and progressive supranuclear palsy (PSP).
Lan Ye, Sam Sadeghi Sani, Linda Veith Sanches, Lea Farina Magdalena Krey, Florian Wegner, Matthias Höllerhage, Christoph Schrader, Günter Höglinger, Martin Klietz   +8 more
doaj   +1 more source

Rest tremor in Parkinson's disease: body distribution and time of appearance [PDF]

, 2017
Objective To assess body distribution and timing of appearance of rest tremor in Parkinson's disease. Methods Information was obtained by a computerized database containing historical information collected at the first visit and data collected during the
Custodero, Giacomo Emanuele, Defazio, Giovanni, Gigante, Angelo Fabio, Guido, Marco, Iliceto, Giovanni, Liuzzi, Daniele, Livrea, Paolo, Mancino, Paola Vincenza, Pellicciari, Roberta   +8 more
core   +1 more source

Functional Connectivity and Volumetrics Improve Outcome Prediction for Deep Brain Stimulation in Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Deep brain stimulation (DBS) targeting the subthalamic nucleus (STN) can effectively treat motor symptoms of Parkinson's disease (PD). However, optimal patient selection remains challenging due to the inadequacy of outcome predictors.
John R. Younce, Scott A. Norris, Mwiza Ushe, Joel S. Perlmutter   +3 more
wiley   +1 more source

Spatial judgment in Parkinson's disease: Contributions of attentional and executive dysfunction [PDF]

, 2019
Spatial judgment is impaired in Parkinson's disease (PD), with previous research suggesting that disruptions in attention and executive function are likely contributors.
Cronin-Golomb, Alice, Moon, Kathryn L.M., Neargarder, Sandy, Salazar, Robert D.   +3 more
core   +1 more source

The Acute Brain Response to Levodopa Heralds Dyskinesias in Parkinson Disease [PDF]

, 2014
OBJECTIVE: In Parkinson disease (PD), long‐term treatment with the dopamine precursor levodopa gradually induces involuntary “dyskinesia” movements. The neural mechanisms underlying the emergence of levodopa‐induced dyskinesias in vivo are still poorly ...
Christensen, Mark S., Haagensen, Brian N., Herz, Damian M., Løkkegaard, Annemette, Madsen, Kristoffer Hougaard, Rowe, James B., Siebner, Hartwig R.   +6 more
core   +1 more source

Action of Thymoxamine on Mydriasis induced by Levodopa and Dopamine [PDF]

, 1971
A. S. D. Spiers, Donald B. Calne, S. D. Vakil, Tristan French   +3 more
openalex   +1 more source

The Persistence of Dopamine Dysregulation Syndrome after Pallidal Deep Brain Stimulation in Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Dopamine dysregulation syndrome (DDS) is a debilitating complication of Parkinson's disease (PD) dopamine replacement therapy (DRT) in which patients pathologically and/or compulsively use dopaminergic drugs to treat motor symptoms. Studies examining DDS outcomes following deep brain stimulation (DBS) are limited and have focused on
Natalie David, Stewart A. Factor, Richa Tripathi, Lenora Higginbotham   +3 more
wiley   +1 more source

Levodopa/benserazide microspheres reduced levodopa-induced dyskinesia by downregulating phosphorylated GluR1 expression in 6-OHDA-lesioned rats

Drug Design, Development and Therapy, 2012
Xinxin Yang,1,* Yinghui Chen,2,* Xiaoyun Hong,3 Na Wu,1 Lu Song,1 Weien Yuan,3 Zhenguo Liu11Department of Neurology, Xinhua Hospital affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China; 2Department of Neurology, Jinshan ...
Song L,Yuan W, Wu N, Hong X, Chen Y, Yang X, Liu Z   +5 more
doaj  

Impact of Istradefylline on Levodopa Dose Escalation in Parkinson’s Disease: ISTRA ADJUST PD Study, a Multicenter, Open-Label, Randomized, Parallel-Group Controlled Study

Neurology and Therapy
Introduction A higher levodopa dose is a risk factor for motor complications in Parkinson’s disease (PD). Istradefylline (IST) is used as adjunctive treatment to levodopa in PD patients with off episodes, but its impact on levodopa dose titration remains
Taku Hatano, Renpei Sengoku, Hiroshi Nagayama, Naotake Yanagisawa, Asako Yoritaka, Keisuke Suzuki, Noriko Nishikawa, Yohei Mukai, Kyoichi Nomura, Norihito Yoshida, Morinobu Seki, Miho Kawabe Matsukawa, Hiroo Terashi, Katsuo Kimura, Jun Tashiro, Shigeki Hirano, Hidetomo Murakami, Hideto Joki, Tsuyoshi Uchiyama, Hideki Shimura, Kotaro Ogaki, Jiro Fukae, Yoshio Tsuboi, Kazushi Takahashi, Toshimasa Yamamoto, Kenichi Kaida, Ryoko Ihara, Kazutomi Kanemaru, Osamu Kano   +28 more
doaj   +1 more source